Logo image of THAR

THARIMMUNE INC (THAR) Stock Fundamental Analysis

NASDAQ:THAR - Nasdaq - US4327053090 - Common Stock - Currency: USD

1.9  +0.04 (+1.99%)

After market: 1.9 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to THAR. THAR was compared to 571 industry peers in the Biotechnology industry. While THAR seems to be doing ok healthwise, there are quite some concerns on its profitability. THAR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year THAR has reported negative net income.
THAR had a negative operating cash flow in the past year.
In the past 5 years THAR always reported negative net income.
THAR had a negative operating cash flow in each of the past 5 years.
THAR Yearly Net Income VS EBIT VS OCF VS FCFTHAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

The Return On Assets of THAR (-206.63%) is worse than 90.94% of its industry peers.
THAR has a worse Return On Equity (-359.59%) than 77.09% of its industry peers.
Industry RankSector Rank
ROA -206.63%
ROE -359.59%
ROIC N/A
ROA(3y)-188.86%
ROA(5y)-1021.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THAR Yearly ROA, ROE, ROICTHAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for THAR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
THAR Yearly Profit, Operating, Gross MarginsTHAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

THAR has more shares outstanding than it did 1 year ago.
There is no outstanding debt for THAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
THAR Yearly Shares OutstandingTHAR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 200K 400K 600K
THAR Yearly Total Debt VS Total AssetsTHAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -14.13, we must say that THAR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -14.13, THAR is not doing good in the industry: 80.99% of the companies in the same industry are doing better.
THAR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.13
ROIC/WACCN/A
WACCN/A
THAR Yearly LT Debt VS Equity VS FCFTHAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M

2.3 Liquidity

THAR has a Current Ratio of 2.35. This indicates that THAR is financially healthy and has no problem in meeting its short term obligations.
THAR has a worse Current ratio (2.35) than 73.00% of its industry peers.
A Quick Ratio of 2.35 indicates that THAR has no problem at all paying its short term obligations.
The Quick ratio of THAR (2.35) is worse than 71.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.35
THAR Yearly Current Assets VS Current LiabilitesTHAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 92.41% over the past year.
EPS 1Y (TTM)92.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, THAR will show a very strong growth in Earnings Per Share. The EPS will grow by 25.98% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.17%
EPS Next 2Y40.13%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
THAR Yearly Revenue VS EstimatesTHAR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026
THAR Yearly EPS VS EstimatesTHAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150 -200 -250

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for THAR. In the last year negative earnings were reported.
Also next year THAR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
THAR Price Earnings VS Forward Price EarningsTHAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
THAR Per share dataTHAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

A more expensive valuation may be justified as THAR's earnings are expected to grow with 25.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.13%
EPS Next 3Y25.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for THAR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THARIMMUNE INC

NASDAQ:THAR (2/21/2025, 8:00:01 PM)

After market: 1.9 0 (0%)

1.9

+0.04 (+1.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2024-08-05/bmo
Earnings (Next)N/A N/A
Inst Owners8.07%
Inst Owner Change-91.5%
Ins Owners1.48%
Ins Owner Change78.11%
Market Cap3.67M
Analysts82.86
Price Target5.1 (168.42%)
Short Float %3.34%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4038.89%
EPS NY rev (3m)-4038.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-198.19
EYN/A
EPS(NY)-7.2
Fwd EYN/A
FCF(TTM)-4.81
FCFYN/A
OCF(TTM)-4.81
OCFYN/A
SpS0
BVpS1.56
TBVpS1.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -206.63%
ROE -359.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.86%
ROA(5y)-1021.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 2.35
Altman-Z -14.13
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.79%
EPS Next Y96.17%
EPS Next 2Y40.13%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-27.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.65%
OCF growth 3YN/A
OCF growth 5YN/A